Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

In the Lucentis Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Ayres shares insights on using a trocar-free, 27-gauge vitrector to improve surgeon comfort and patient safety in anterior ...

A phase 2 trial of GRF312 immunoglobulin eye drops for dry eye disease is expected to begin later this year. The drops target multiple mechanisms of inflammation in chronic dry eye disease.

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

It's a shadow of that debris that's in the center of the eye. You will notice it more against a bright sky or a white wall. And again and come. Floaters are very common. But you want to monitor ...

I read an article a few years back that said if you had vertigo, you more than likely would also have restless legs syndrome ...